Registration for a live webinar on 'Gamma-delta T cells for immunotherapy of cancer' is now open.See webinar details
Talimogene laherparepvec: first-in-class oncolytic immunotherapy
Published on November 30, 2016 44 min
Other Talks in the Series: Immunotherapy of Cancer
Hello, my name is Kevin Harrington. I work at the Institute of Cancer Research in London. I have a long-standing interest in the development of oncolytic viruses as cancer therapies. Today, I will be discussing Talimogene Laherparepvec: a First-in-Class Oncolytic Immunotherapy.
Here are my disclosures.
For many years, we have been interested in the use of viruses as potential therapies for cancer. And on this slide, you can see a small number of viruses that have been in active preclinical and clinical evaluation in the last two decades. The rest of this talk is going to focus on a single example of this which is the Herpes simplex virus, which is now a registered therapy with an approval for the treatment of melanoma in the USA, in Europe, and in Australasia.
The principle of oncolytic viruses rests on the fact that certain viruses are capable of infecting normal cells where they will trigger a potent antiviral response, mainly based around interferon signaling. And this antiviral response will shut down viral replication and then as an additional safety measure will frequently trigger the cell into apoptosis, thereby protecting the host against productive viral infection. In certain situations, these same viruses, if they find themselves infecting a cancer cell, will be able to replicate. And this is usually based around the fact that tumor cells frequently lack normal antiviral interferon signaling responses. As a consequence, the productive replication of virus is capable of mediating a process of tumor lysis so called oncolysis, leading to the release of daughter virions, which have the potential to cause a cycle of ongoing replication and infection in other tumor cells, potentially leading to a cancer specific infection.